Last reviewed · How we verify
Candesartan Thiazide
Candesartan thiazide is a combination drug that blocks angiotensin II receptors to lower blood pressure while a thiazide diuretic enhances sodium and water excretion.
Candesartan thiazide is a combination drug that blocks angiotensin II receptors to lower blood pressure while a thiazide diuretic enhances sodium and water excretion. Used for Hypertension.
At a glance
| Generic name | Candesartan Thiazide |
|---|---|
| Sponsor | Institut de Recherches Cliniques de Montreal |
| Drug class | Angiotensin II receptor blocker / Thiazide diuretic combination |
| Target | AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Candesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels, causing vasodilation and reduced blood pressure. The thiazide component acts as a diuretic, promoting renal sodium and water excretion to further reduce blood volume and blood pressure. This dual mechanism provides additive antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Fatigue
- Hyperuricemia
- Hypokalemia
- Hyperglycemia
- Cough
Key clinical trials
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)
- A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323 (PHASE1)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide (PHASE3)
- Pharmacodynamic Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Hypertensive Patients. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |